[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20014864D0 - Substituerte 1,4-dihydro-inden [1,2-C] pyrazoler som inhibitorer av tyrosin kinase - Google Patents

Substituerte 1,4-dihydro-inden [1,2-C] pyrazoler som inhibitorer av tyrosin kinase

Info

Publication number
NO20014864D0
NO20014864D0 NO20014864A NO20014864A NO20014864D0 NO 20014864 D0 NO20014864 D0 NO 20014864D0 NO 20014864 A NO20014864 A NO 20014864A NO 20014864 A NO20014864 A NO 20014864A NO 20014864 D0 NO20014864 D0 NO 20014864D0
Authority
NO
Norway
Prior art keywords
pyrazoles
inhibitors
dihydroindene
substituted
tyrosine kinase
Prior art date
Application number
NO20014864A
Other languages
English (en)
Other versions
NO20014864L (no
Inventor
Kevin J Doyle
Paul Rafferty
Robert William Steele
Allyson Turner
David J Wilkins
Lee Daniel Arnold
Original Assignee
Knoll Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Gmbh filed Critical Knoll Gmbh
Publication of NO20014864D0 publication Critical patent/NO20014864D0/no
Publication of NO20014864L publication Critical patent/NO20014864L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20014864A 1999-04-06 2001-10-05 Substituerte 1,4-dihydro-indeno [1,2-C] pyrazoler som inhibitorer av tyrosin kinase NO20014864L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12796399P 1999-04-06 1999-04-06
PCT/US2000/008192 WO2000059901A1 (en) 1999-04-06 2000-03-28 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase

Publications (2)

Publication Number Publication Date
NO20014864D0 true NO20014864D0 (no) 2001-10-05
NO20014864L NO20014864L (no) 2001-12-05

Family

ID=22432894

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014864A NO20014864L (no) 1999-04-06 2001-10-05 Substituerte 1,4-dihydro-indeno [1,2-C] pyrazoler som inhibitorer av tyrosin kinase

Country Status (25)

Country Link
EP (1) EP1165544B1 (no)
JP (1) JP2002541150A (no)
KR (1) KR20020015034A (no)
CN (1) CN1368970A (no)
AT (1) ATE246684T1 (no)
AU (1) AU4037800A (no)
BG (1) BG106044A (no)
BR (1) BR0009561A (no)
CA (1) CA2368686A1 (no)
CZ (1) CZ20013580A3 (no)
DE (1) DE60004340T2 (no)
DK (1) DK1165544T3 (no)
ES (1) ES2207497T3 (no)
HK (1) HK1045500A1 (no)
HU (1) HUP0201514A3 (no)
IL (1) IL145564A0 (no)
MX (1) MXPA01010072A (no)
NO (1) NO20014864L (no)
NZ (1) NZ514269A (no)
PL (1) PL350891A1 (no)
PT (1) PT1165544E (no)
SK (1) SK14112001A3 (no)
TR (1) TR200103789T2 (no)
WO (1) WO2000059901A1 (no)
ZA (1) ZA200107838B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
US6297238B1 (en) * 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
CA2461567C (en) * 2001-09-19 2008-08-19 Pharmacia Corporation Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
BR0212611A (pt) 2001-09-19 2004-08-17 Pharmacia Corp Compostos de pirazolila substituìdos para o tratamento da inflamação
DE60311567T2 (de) * 2002-02-19 2007-10-31 Pfizer Italia S.R.L. Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel
EP1506175B1 (en) * 2002-05-15 2009-04-01 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdgf receptor inhibitors
US20060264493A1 (en) * 2003-02-17 2006-11-23 Ermes Vanotti Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
ES2545666T3 (es) * 2003-02-27 2015-09-14 Abbvie Inc. 5,10-Dihidro-11H-dibenzo[b,e][1,4]diazepin-11-ona como inhibidores de quinasa
US7320986B2 (en) 2003-03-07 2008-01-22 Abbott Labortories Fused tri and tetra-cyclic pyrazole kinase inhibitors
JP2006520400A (ja) * 2003-03-07 2006-09-07 アボット・ラボラトリーズ 縮合三および四環式ピラゾールキナーゼ阻害剤
ES2551293T3 (es) 2004-03-24 2015-11-17 Abbvie Inc. Inhibidores de quinasas de pirazol tricíclicos
CA2725185C (en) * 2008-05-23 2016-10-25 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
US8853207B2 (en) 2012-04-12 2014-10-07 Development Center For Biotechnology Heterocyclic pyrazole compounds, method for preparing the same and use thereof
CN104610149B (zh) * 2015-02-10 2017-04-05 山东大学 一种茚并吡唑类小分子微管蛋白抑制剂及其制备方法与应用
WO2025031474A1 (en) * 2023-08-10 2025-02-13 Insilico Medicine Ip Limited Method and medicament for treating endometriosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
WO1999017770A1 (en) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft Indeno[1,2-c]pyrazole derivatives for inhibiting tyrosine kinase activity
CN1335836A (zh) * 1998-11-06 2002-02-13 巴斯福股份公司 三环吡唑衍生物

Also Published As

Publication number Publication date
DE60004340T2 (de) 2004-06-09
ES2207497T3 (es) 2004-06-01
EP1165544B1 (en) 2003-08-06
HUP0201514A3 (en) 2003-11-28
WO2000059901A1 (en) 2000-10-12
CN1368970A (zh) 2002-09-11
BG106044A (en) 2002-05-31
DE60004340D1 (de) 2003-09-11
MXPA01010072A (es) 2004-03-26
SK14112001A3 (sk) 2002-04-04
EP1165544A1 (en) 2002-01-02
ATE246684T1 (de) 2003-08-15
TR200103789T2 (tr) 2002-04-22
PL350891A1 (en) 2003-02-10
JP2002541150A (ja) 2002-12-03
ZA200107838B (en) 2003-03-24
IL145564A0 (en) 2002-06-30
HK1045500A1 (zh) 2002-11-29
HUP0201514A2 (en) 2002-08-28
CZ20013580A3 (cs) 2002-03-13
KR20020015034A (ko) 2002-02-27
BR0009561A (pt) 2002-04-16
NZ514269A (en) 2003-10-31
DK1165544T3 (da) 2003-12-01
NO20014864L (no) 2001-12-05
AU4037800A (en) 2000-10-23
PT1165544E (pt) 2003-12-31
CA2368686A1 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
NO20005535L (no) Pyrazol-derivater som P-38 MAP kinase-inhibitorer
MXPA02011320A (es) Derivados de pirazol triciclico como inhibidores de cinasa.
NO20014864L (no) Substituerte 1,4-dihydro-indeno [1,2-C] pyrazoler som inhibitorer av tyrosin kinase
MXPA03010207A (es) Nuevas 4-anilinoquinolin-3-carboxamidas.
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
BR9915132A (pt) Método para inibir a atividade de quinase de proteìna, compostos da fórmula i e sais farmaceuticamente aceitáveis dos mesmos, uso do mesmo, e, composição farmacêutica.
ATE377597T1 (de) Anilinochinazoline als protein-tyrosin- kinasehemmer
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
BR0014225A (pt) Derivados de pirazol
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
DE69824029D1 (de) Bicyclische kinase inhibitoren
ATE300541T1 (de) Pyrazolopyridinderivate
WO2002018321A3 (en) Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors
NO20040589L (no) Arylsulfonylderivater med 5-HT6 reseptor affinitet.
MXPA04005426A (es) Derivados de pirazol de anillos fuisionados.
MXPA04005809A (es) Inhibidores de proteinas quinasas.
NO983444L (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
ATE274515T1 (de) Pyrazolopyridinderivate
WO2002018323A3 (en) Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors
WO2002018363A3 (en) 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors
ATE363481T1 (de) Pyrazolderivate als gnrh-inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application